| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Giant Cell Arteritis | 6 | 2018 | 137 | 2.65 | Why? |
| Myocardium | 8 | 2021 | 2323 | 1.82 | Why? |
| Prednisone | 3 | 2018 | 652 | 1.52 | Why? |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 6 | 2019 | 235 | 1.16 | Why? |
| Receptors, Interleukin-6 | 4 | 2020 | 1383 | 1.08 | Why? |
| Rituximab | 7 | 2019 | 1096 | 1.07 | Why? |
| Glucocorticoids | 11 | 2021 | 4431 | 1.01 | Why? |
| Autoimmune Hypophysitis | 2 | 2018 | 3 | 0.98 | Why? |
| Temporal Arteries | 2 | 2018 | 35 | 0.88 | Why? |
| Granulomatosis with Polyangiitis | 7 | 2018 | 161 | 0.80 | Why? |
| Orbital Pseudotumor | 1 | 2018 | 5 | 0.79 | Why? |
| Immunoglobulin G | 13 | 2019 | 21571 | 0.78 | Why? |
| Orbital Myositis | 1 | 2018 | 6 | 0.77 | Why? |
| Antibodies, Monoclonal, Humanized | 7 | 2021 | 9335 | 0.77 | Why? |
| Retroperitoneal Fibrosis | 1 | 2018 | 20 | 0.75 | Why? |
| Lipomatosis | 1 | 2017 | 4 | 0.73 | Why? |
| Pheochromocytoma | 1 | 2018 | 32 | 0.72 | Why? |
| Exostoses, Multiple Hereditary | 1 | 2017 | 3 | 0.72 | Why? |
| Saphenous Vein | 1 | 2018 | 67 | 0.71 | Why? |
| Popliteal Artery | 1 | 2017 | 32 | 0.69 | Why? |
| Adrenal Gland Neoplasms | 1 | 2018 | 70 | 0.68 | Why? |
| Aortitis | 1 | 2017 | 39 | 0.67 | Why? |
| Adrenal Glands | 1 | 2018 | 98 | 0.66 | Why? |
| Iron Overload | 1 | 2019 | 113 | 0.66 | Why? |
| Receptors, Cholinergic | 1 | 2017 | 70 | 0.66 | Why? |
| Plasma Cells | 2 | 2017 | 464 | 0.65 | Why? |
| Aneurysm | 1 | 2018 | 117 | 0.65 | Why? |
| Meningitis | 1 | 2018 | 163 | 0.65 | Why? |
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2017 | 51 | 0.64 | Why? |
| Coronary Aneurysm | 1 | 2018 | 132 | 0.64 | Why? |
| Intracranial Hypertension | 1 | 2018 | 111 | 0.63 | Why? |
| Autoimmune Diseases of the Nervous System | 1 | 2017 | 141 | 0.63 | Why? |
| Myocarditis | 4 | 2021 | 2731 | 0.63 | Why? |
| Aneurysm, False | 1 | 2017 | 88 | 0.61 | Why? |
| Antibodies, Antineutrophil Cytoplasmic | 3 | 2019 | 140 | 0.61 | Why? |
| Blindness | 1 | 2018 | 130 | 0.61 | Why? |
| Vasculitis | 5 | 2017 | 691 | 0.61 | Why? |
| Mesenteric Arteries | 1 | 2014 | 22 | 0.60 | Why? |
| Peripheral Nervous System Diseases | 1 | 2018 | 193 | 0.59 | Why? |
| Amyloidosis | 1 | 2017 | 178 | 0.59 | Why? |
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 243 | 0.59 | Why? |
| Syncope | 1 | 2018 | 238 | 0.58 | Why? |
| Tachycardia, Ventricular | 1 | 2018 | 251 | 0.57 | Why? |
| Edema | 2 | 2017 | 333 | 0.57 | Why? |
| Erythrocyte Transfusion | 1 | 2019 | 386 | 0.57 | Why? |
| Purpura | 2 | 2017 | 310 | 0.56 | Why? |
| Mesenteric Vascular Occlusion | 1 | 2014 | 43 | 0.56 | Why? |
| Adenocarcinoma | 2 | 2019 | 651 | 0.55 | Why? |
| Diagnosis, Differential | 12 | 2019 | 7220 | 0.55 | Why? |
| Heart | 4 | 2021 | 1791 | 0.51 | Why? |
| Iron | 1 | 2019 | 619 | 0.50 | Why? |
| Cardiovascular System | 1 | 2021 | 750 | 0.50 | Why? |
| Mesenteric Ischemia | 1 | 2014 | 128 | 0.49 | Why? |
| Central Nervous System Diseases | 1 | 2018 | 410 | 0.48 | Why? |
| Antineoplastic Agents, Immunological | 1 | 2019 | 830 | 0.47 | Why? |
| Adipose Tissue | 1 | 2017 | 612 | 0.47 | Why? |
| Coronary Artery Bypass | 1 | 2018 | 629 | 0.46 | Why? |
| Takotsubo Cardiomyopathy | 1 | 2018 | 453 | 0.45 | Why? |
| Diagnostic Errors | 1 | 2018 | 865 | 0.44 | Why? |
| Shock, Cardiogenic | 1 | 2018 | 700 | 0.44 | Why? |
| Pulmonary Artery | 1 | 2018 | 803 | 0.43 | Why? |
| Myasthenia Gravis | 1 | 2017 | 385 | 0.43 | Why? |
| Cardiomyopathies | 1 | 2020 | 997 | 0.43 | Why? |
| Heart Transplantation | 2 | 2019 | 1293 | 0.43 | Why? |
| Gastrointestinal Hemorrhage | 1 | 2017 | 669 | 0.42 | Why? |
| Autopsy | 6 | 2021 | 3495 | 0.42 | Why? |
| Ventricular Dysfunction, Left | 1 | 2019 | 993 | 0.41 | Why? |
| Submandibular Gland | 1 | 2009 | 29 | 0.41 | Why? |
| Blast Injuries | 2 | 2019 | 20 | 0.40 | Why? |
| Sialadenitis | 1 | 2009 | 31 | 0.39 | Why? |
| Fatal Outcome | 5 | 2020 | 3438 | 0.39 | Why? |
| Magnetic Resonance Imaging | 9 | 2020 | 6551 | 0.38 | Why? |
| Remission Induction | 5 | 2019 | 950 | 0.37 | Why? |
| Cyclophosphamide | 4 | 2019 | 387 | 0.35 | Why? |
| Autoimmune Diseases | 2 | 2018 | 1996 | 0.35 | Why? |
| B-Lymphocytes | 6 | 2019 | 4418 | 0.35 | Why? |
| Multiple Myeloma | 1 | 2017 | 1064 | 0.35 | Why? |
| Electrocardiography | 5 | 2021 | 3957 | 0.35 | Why? |
| Biopsy | 5 | 2019 | 2811 | 0.33 | Why? |
| Immunosuppressive Agents | 6 | 2021 | 6331 | 0.33 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2018 | 1380 | 0.32 | Why? |
| Immunologic Factors | 4 | 2018 | 4206 | 0.31 | Why? |
| Tunica Intima | 1 | 2005 | 27 | 0.31 | Why? |
| Arteriosclerosis | 1 | 2005 | 50 | 0.30 | Why? |
| Cerebrovascular Circulation | 2 | 2019 | 340 | 0.30 | Why? |
| Mammary Arteries | 1 | 2005 | 31 | 0.30 | Why? |
| Venous Thromboembolism | 3 | 2018 | 4273 | 0.29 | Why? |
| Extracellular Matrix Proteins | 1 | 2005 | 95 | 0.29 | Why? |
| Endovascular Procedures | 1 | 2014 | 1302 | 0.28 | Why? |
| Recurrence | 4 | 2018 | 3675 | 0.28 | Why? |
| Proteoglycans | 1 | 2005 | 130 | 0.28 | Why? |
| Lung Neoplasms | 2 | 2019 | 3228 | 0.27 | Why? |
| Myeloblastin | 3 | 2019 | 57 | 0.27 | Why? |
| Embolization, Therapeutic | 2 | 2017 | 269 | 0.27 | Why? |
| Brain Injuries, Traumatic | 2 | 2019 | 381 | 0.27 | Why? |
| Humans | 71 | 2021 | 930598 | 0.26 | Why? |
| Carotid Arteries | 1 | 2005 | 182 | 0.26 | Why? |
| Double-Blind Method | 6 | 2020 | 5988 | 0.25 | Why? |
| Liver Transplantation | 1 | 2019 | 2864 | 0.24 | Why? |
| In Situ Hybridization | 2 | 2021 | 390 | 0.24 | Why? |
| Lymphoma | 2 | 2017 | 522 | 0.24 | Why? |
| Lectins, C-Type | 1 | 2005 | 405 | 0.24 | Why? |
| Drug Therapy, Combination | 5 | 2021 | 7268 | 0.24 | Why? |
| Coronary Vessels | 2 | 2020 | 914 | 0.23 | Why? |
| Muscle Cells | 1 | 2020 | 40 | 0.22 | Why? |
| Male | 41 | 2021 | 367725 | 0.22 | Why? |
| Middle Aged | 37 | 2021 | 270681 | 0.22 | Why? |
| Microscopic Polyangiitis | 2 | 2018 | 31 | 0.22 | Why? |
| Echocardiography | 3 | 2021 | 3661 | 0.21 | Why? |
| Female | 39 | 2021 | 380317 | 0.21 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.21 | Why? |
| Biomedical Research | 1 | 2021 | 5270 | 0.21 | Why? |
| Endocardium | 1 | 2020 | 90 | 0.21 | Why? |
| Bone Marrow | 2 | 2021 | 492 | 0.21 | Why? |
| Arterioles | 1 | 2019 | 24 | 0.21 | Why? |
| Aged | 28 | 2021 | 215776 | 0.21 | Why? |
| Receptors, Phospholipase A2 | 1 | 2019 | 14 | 0.20 | Why? |
| Exophthalmos | 1 | 2018 | 17 | 0.20 | Why? |
| Mass Spectrometry | 1 | 2005 | 1165 | 0.19 | Why? |
| Cell Cycle Checkpoints | 1 | 2019 | 126 | 0.19 | Why? |
| Inflammation | 4 | 2021 | 13255 | 0.19 | Why? |
| Transferrin | 1 | 2019 | 90 | 0.19 | Why? |
| Immunohistochemistry | 3 | 2021 | 2275 | 0.19 | Why? |
| Intramolecular Oxidoreductases | 1 | 2018 | 38 | 0.19 | Why? |
| Signaling Lymphocytic Activation Molecule Family | 1 | 2018 | 22 | 0.19 | Why? |
| Macrophage Migration-Inhibitory Factors | 1 | 2018 | 39 | 0.19 | Why? |
| Orbit | 1 | 2018 | 51 | 0.19 | Why? |
| Filamins | 1 | 2017 | 7 | 0.19 | Why? |
| Retroperitoneal Space | 1 | 2018 | 68 | 0.18 | Why? |
| Anti-Inflammatory Agents | 1 | 2018 | 6153 | 0.18 | Why? |
| Marmota | 1 | 2017 | 19 | 0.18 | Why? |
| Glomerulonephritis, Membranous | 1 | 2019 | 71 | 0.18 | Why? |
| Intubation | 1 | 2020 | 437 | 0.18 | Why? |
| CD8 Antigens | 1 | 2018 | 72 | 0.18 | Why? |
| CD4-Positive T-Lymphocytes | 3 | 2018 | 4545 | 0.18 | Why? |
| Enbucrilate | 1 | 2017 | 7 | 0.18 | Why? |
| Diplopia | 1 | 2018 | 84 | 0.18 | Why? |
| Pericardium | 1 | 2020 | 228 | 0.18 | Why? |
| Endarterectomy | 1 | 2018 | 60 | 0.18 | Why? |
| Ureteral Diseases | 1 | 2017 | 26 | 0.18 | Why? |
| Stroke Volume | 2 | 2019 | 2153 | 0.18 | Why? |
| Neoplasms, Plasma Cell | 1 | 2017 | 83 | 0.18 | Why? |
| Cardiomyopathy, Restrictive | 1 | 2017 | 30 | 0.18 | Why? |
| HLA-DP beta-Chains | 1 | 2017 | 8 | 0.18 | Why? |
| Hypotension, Orthostatic | 1 | 2018 | 55 | 0.18 | Why? |
| Cytoplasm | 1 | 2019 | 304 | 0.18 | Why? |
| Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2017 | 7 | 0.18 | Why? |
| Treatment Outcome | 12 | 2019 | 51732 | 0.17 | Why? |
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2016 | 10 | 0.17 | Why? |
| Spinal Puncture | 1 | 2018 | 95 | 0.17 | Why? |
| Septal Occluder Device | 1 | 2017 | 46 | 0.17 | Why? |
| Lung | 7 | 2021 | 31049 | 0.17 | Why? |
| Clonal Evolution | 1 | 2017 | 55 | 0.17 | Why? |
| Polypharmacy | 1 | 2020 | 347 | 0.17 | Why? |
| Kidney | 3 | 2021 | 3648 | 0.17 | Why? |
| Diagnostic Techniques, Ophthalmological | 1 | 2018 | 136 | 0.17 | Why? |
| Boston | 1 | 2020 | 929 | 0.17 | Why? |
| Astrocytes | 1 | 2019 | 298 | 0.16 | Why? |
| Amyloid | 1 | 2017 | 156 | 0.16 | Why? |
| Ventricular Dysfunction | 1 | 2018 | 150 | 0.16 | Why? |
| White Matter | 1 | 2020 | 369 | 0.16 | Why? |
| Vena Cava Filters | 1 | 2017 | 89 | 0.16 | Why? |
| Stomach | 1 | 2017 | 141 | 0.16 | Why? |
| Phenylurea Compounds | 1 | 2016 | 101 | 0.15 | Why? |
| Urinalysis | 1 | 2018 | 218 | 0.15 | Why? |
| Hematuria | 1 | 2018 | 284 | 0.15 | Why? |
| Epistaxis | 1 | 2017 | 96 | 0.15 | Why? |
| Cardiovascular Diseases | 1 | 2021 | 11497 | 0.15 | Why? |
| Tomography, X-Ray Computed | 6 | 2019 | 25144 | 0.15 | Why? |
| Giant Cells | 1 | 2018 | 334 | 0.15 | Why? |
| Confusion | 1 | 2017 | 256 | 0.15 | Why? |
| Flow Cytometry | 3 | 2018 | 2393 | 0.15 | Why? |
| Splanchnic Circulation | 1 | 2014 | 37 | 0.15 | Why? |
| Dyspnea | 2 | 2019 | 3847 | 0.14 | Why? |
| Injections, Subcutaneous | 1 | 2017 | 647 | 0.14 | Why? |
| Cytotoxicity, Immunologic | 1 | 2017 | 287 | 0.14 | Why? |
| Chest Pain | 1 | 2019 | 578 | 0.14 | Why? |
| Glomerulonephritis | 1 | 2018 | 226 | 0.14 | Why? |
| Predictive Value of Tests | 4 | 2021 | 9537 | 0.14 | Why? |
| Neurologic Examination | 1 | 2018 | 428 | 0.14 | Why? |
| Promoter Regions, Genetic | 1 | 2018 | 823 | 0.14 | Why? |
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 290 | 0.14 | Why? |
| Liver | 2 | 2021 | 4007 | 0.14 | Why? |
| Treatment Failure | 1 | 2020 | 2106 | 0.14 | Why? |
| Echocardiography, Transesophageal | 1 | 2018 | 447 | 0.14 | Why? |
| Cholangiocarcinoma | 1 | 2016 | 186 | 0.13 | Why? |
| Vision Disorders | 1 | 2018 | 260 | 0.13 | Why? |
| Proteinuria | 1 | 2018 | 474 | 0.13 | Why? |
| Hematologic Diseases | 1 | 2021 | 614 | 0.13 | Why? |
| Bile Duct Neoplasms | 1 | 2016 | 172 | 0.13 | Why? |
| alpha 1-Antitrypsin | 1 | 2017 | 264 | 0.13 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2018 | 552 | 0.13 | Why? |
| Translocation, Genetic | 1 | 2013 | 40 | 0.13 | Why? |
| Back Pain | 1 | 2014 | 115 | 0.13 | Why? |
| Respiratory Therapy | 1 | 2020 | 918 | 0.13 | Why? |
| Prednisolone | 1 | 2016 | 443 | 0.13 | Why? |
| Aged, 80 and over | 11 | 2021 | 88759 | 0.13 | Why? |
| Immune System Diseases | 1 | 2017 | 410 | 0.13 | Why? |
| Peroxidase | 3 | 2019 | 207 | 0.13 | Why? |
| Positron-Emission Tomography | 1 | 2018 | 802 | 0.12 | Why? |
| Drug Resistance, Neoplasm | 1 | 2016 | 447 | 0.12 | Why? |
| Radiography, Interventional | 1 | 2014 | 158 | 0.12 | Why? |
| Syndrome | 1 | 2018 | 1310 | 0.12 | Why? |
| Glaucoma | 1 | 2016 | 225 | 0.12 | Why? |
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 800 | 0.12 | Why? |
| Pain | 2 | 2017 | 1084 | 0.12 | Why? |
| Primary Ovarian Insufficiency | 1 | 2011 | 19 | 0.12 | Why? |
| Protein-Tyrosine Kinases | 1 | 2013 | 158 | 0.12 | Why? |
| Interleukin-6 | 2 | 2021 | 7522 | 0.12 | Why? |
| Fatigue | 3 | 2018 | 2479 | 0.12 | Why? |
| Spondylitis, Ankylosing | 1 | 2014 | 231 | 0.12 | Why? |
| Severity of Illness Index | 2 | 2018 | 48226 | 0.12 | Why? |
| Adult | 22 | 2021 | 244371 | 0.12 | Why? |
| Macrophages | 2 | 2020 | 2784 | 0.11 | Why? |
| Withholding Treatment | 1 | 2018 | 798 | 0.11 | Why? |
| Defibrillators, Implantable | 1 | 2018 | 624 | 0.11 | Why? |
| Osteoporosis | 1 | 2016 | 410 | 0.11 | Why? |
| Ovary | 1 | 2011 | 133 | 0.11 | Why? |
| Proto-Oncogene Proteins | 1 | 2013 | 340 | 0.11 | Why? |
| Exanthema | 2 | 2017 | 1097 | 0.11 | Why? |
| Drug Resistance | 1 | 2013 | 395 | 0.10 | Why? |
| Sublingual Gland | 1 | 2009 | 2 | 0.10 | Why? |
| Leukocytes | 1 | 2017 | 1046 | 0.10 | Why? |
| Combined Modality Therapy | 1 | 2019 | 3395 | 0.10 | Why? |
| Headache | 2 | 2018 | 2257 | 0.10 | Why? |
| Biomarkers | 5 | 2021 | 23361 | 0.10 | Why? |
| Ferritins | 1 | 2019 | 2055 | 0.10 | Why? |
| Ventricular Function, Left | 1 | 2019 | 1555 | 0.10 | Why? |
| Heart-Assist Devices | 1 | 2018 | 812 | 0.10 | Why? |
| Troponin I | 1 | 2018 | 1298 | 0.10 | Why? |
| T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.09 | Why? |
| Disease Susceptibility | 2 | 2017 | 4002 | 0.09 | Why? |
| Time Factors | 5 | 2019 | 31397 | 0.09 | Why? |
| Genetic Predisposition to Disease | 3 | 2018 | 4027 | 0.09 | Why? |
| Pyrimidines | 1 | 2016 | 1557 | 0.09 | Why? |
| Coronary Angiography | 1 | 2018 | 2275 | 0.09 | Why? |
| Interferons | 1 | 2020 | 2885 | 0.09 | Why? |
| Neutrophils | 3 | 2019 | 5476 | 0.09 | Why? |
| Methotrexate | 1 | 2011 | 471 | 0.09 | Why? |
| Vascular Diseases | 1 | 2016 | 846 | 0.08 | Why? |
| Carcinoma, Hepatocellular | 1 | 2017 | 1222 | 0.08 | Why? |
| Cytokines | 3 | 2018 | 15010 | 0.08 | Why? |
| Pyridines | 1 | 2013 | 680 | 0.08 | Why? |
| Disease Progression | 3 | 2021 | 13580 | 0.08 | Why? |
| Neck | 1 | 2009 | 307 | 0.08 | Why? |
| Reproducibility of Results | 3 | 2021 | 11304 | 0.08 | Why? |
| Blood Pressure | 1 | 2018 | 2198 | 0.08 | Why? |
| Heart Failure | 2 | 2019 | 6638 | 0.08 | Why? |
| Aggrecans | 1 | 2005 | 6 | 0.08 | Why? |
| Sjogren's Syndrome | 1 | 2009 | 284 | 0.08 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.08 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2020 | 2984 | 0.08 | Why? |
| Liver Neoplasms | 1 | 2017 | 1666 | 0.07 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.07 | Why? |
| Kidney Failure, Chronic | 2 | 2018 | 3222 | 0.07 | Why? |
| Ear | 1 | 2004 | 51 | 0.07 | Why? |
| Skin | 1 | 2017 | 2096 | 0.07 | Why? |
| Peripheral Nerves | 1 | 2004 | 74 | 0.07 | Why? |
| Etanercept | 2 | 2018 | 162 | 0.07 | Why? |
| Protein Kinase Inhibitors | 1 | 2013 | 1585 | 0.06 | Why? |
| Disease Models, Animal | 2 | 2018 | 10998 | 0.06 | Why? |
| Pyrazoles | 1 | 2013 | 1791 | 0.06 | Why? |
| Radiography, Thoracic | 1 | 2019 | 5486 | 0.06 | Why? |
| Mutation | 3 | 2017 | 12376 | 0.06 | Why? |
| Genome-Wide Association Study | 2 | 2021 | 1648 | 0.06 | Why? |
| Acute Disease | 1 | 2014 | 6029 | 0.06 | Why? |
| Myocardial Infarction | 1 | 2017 | 3361 | 0.06 | Why? |
| Aspartic Acid Endopeptidases | 1 | 2020 | 57 | 0.06 | Why? |
| Atlases as Topic | 1 | 2021 | 166 | 0.06 | Why? |
| Rats | 2 | 2019 | 2764 | 0.06 | Why? |
| Animals | 7 | 2019 | 78931 | 0.05 | Why? |
| Heart Diseases | 1 | 2018 | 3503 | 0.05 | Why? |
| Eosinophilia | 1 | 2004 | 292 | 0.05 | Why? |
| Risk Factors | 4 | 2019 | 71621 | 0.05 | Why? |
| Antineoplastic Agents | 1 | 2016 | 3550 | 0.05 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.05 | Why? |
| Rats, Long-Evans | 1 | 2019 | 3 | 0.05 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 4 | 2021 | 10649 | 0.05 | Why? |
| Phagocytes | 1 | 2021 | 180 | 0.05 | Why? |
| Skin Diseases | 1 | 2017 | 2509 | 0.05 | Why? |
| Mucins | 1 | 2020 | 147 | 0.05 | Why? |
| Sensitivity and Specificity | 2 | 2018 | 22971 | 0.05 | Why? |
| Eye | 1 | 2004 | 374 | 0.05 | Why? |
| Weight Loss | 2 | 2017 | 826 | 0.05 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.05 | Why? |
| Photoacoustic Techniques | 1 | 2019 | 31 | 0.05 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.05 | Why? |
| Gray Matter | 1 | 2020 | 150 | 0.05 | Why? |
| T-Lymphocytes | 1 | 2017 | 6670 | 0.05 | Why? |
| Cytokine Receptor Common beta Subunit | 1 | 2017 | 4 | 0.05 | Why? |
| Azathioprine | 1 | 2019 | 161 | 0.05 | Why? |
| Epithelial Cells | 2 | 2021 | 3508 | 0.05 | Why? |
| Surface-Active Agents | 1 | 2020 | 267 | 0.05 | Why? |
| Hippocampus | 1 | 2020 | 237 | 0.04 | Why? |
| Registries | 1 | 2018 | 12327 | 0.04 | Why? |
| Hypergammaglobulinemia | 1 | 2017 | 5 | 0.04 | Why? |
| Microsatellite Repeats | 1 | 2018 | 99 | 0.04 | Why? |
| Pulmonary Embolism | 1 | 2017 | 4775 | 0.04 | Why? |
| Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 198 | 0.04 | Why? |
| Transcription Factor TFIIIA | 1 | 2016 | 2 | 0.04 | Why? |
| Dose-Response Relationship, Drug | 2 | 2018 | 3776 | 0.04 | Why? |
| Granzymes | 1 | 2018 | 197 | 0.04 | Why? |
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 9 | 0.04 | Why? |
| Nose | 1 | 2004 | 1093 | 0.04 | Why? |
| Perforin | 1 | 2018 | 136 | 0.04 | Why? |
| Reagent Strips | 1 | 2018 | 129 | 0.04 | Why? |
| Angiography, Digital Subtraction | 1 | 2017 | 123 | 0.04 | Why? |
| Regeneration | 1 | 2021 | 429 | 0.04 | Why? |
| HLA-DP Antigens | 1 | 2017 | 38 | 0.04 | Why? |
| Young Adult | 5 | 2020 | 93724 | 0.04 | Why? |
| Sweating | 1 | 2017 | 52 | 0.04 | Why? |
| Gene Fusion | 1 | 2016 | 25 | 0.04 | Why? |
| Gene Expression | 2 | 2018 | 3332 | 0.04 | Why? |
| Mice, Inbred C57BL | 2 | 2018 | 5542 | 0.04 | Why? |
| Circulating Tumor DNA | 1 | 2016 | 46 | 0.04 | Why? |
| Immunoglobulin Class Switching | 1 | 2017 | 133 | 0.04 | Why? |
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2018 | 203 | 0.04 | Why? |
| Fibroblasts | 1 | 2021 | 839 | 0.04 | Why? |
| Organ Specificity | 1 | 2021 | 1070 | 0.04 | Why? |
| Pharynx | 1 | 2004 | 1544 | 0.04 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.04 | Why? |
| RNA, Viral | 2 | 2021 | 32276 | 0.04 | Why? |
| Pulmonary Alveoli | 1 | 2021 | 867 | 0.04 | Why? |
| Cause of Death | 2 | 2021 | 4823 | 0.04 | Why? |
| Influenza, Human | 1 | 2020 | 10779 | 0.04 | Why? |
| Rats, Sprague-Dawley | 1 | 2019 | 987 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Membrane Transport Proteins | 1 | 2016 | 152 | 0.04 | Why? |
| Knee | 1 | 2014 | 35 | 0.04 | Why? |
| HLA-B27 Antigen | 1 | 2014 | 48 | 0.04 | Why? |
| Cell Cycle Proteins | 1 | 2016 | 297 | 0.03 | Why? |
| Monocytes | 2 | 2017 | 2978 | 0.03 | Why? |
| Cell Communication | 1 | 2017 | 396 | 0.03 | Why? |
| Prosthesis Design | 1 | 2017 | 594 | 0.03 | Why? |
| Chronic Disease | 1 | 2009 | 5139 | 0.03 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2018 | 3607 | 0.03 | Why? |
| Heart Block | 1 | 2014 | 59 | 0.03 | Why? |
| Diabetes Mellitus | 1 | 2016 | 8207 | 0.03 | Why? |
| Autoantigens | 1 | 2017 | 388 | 0.03 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.03 | Why? |
| Proteomics | 1 | 2005 | 2481 | 0.03 | Why? |
| Thoracic Vertebrae | 1 | 2014 | 97 | 0.03 | Why? |
| Infusions, Intravenous | 1 | 2018 | 1224 | 0.03 | Why? |
| Gene Frequency | 1 | 2018 | 1210 | 0.03 | Why? |
| Haplotypes | 1 | 2017 | 853 | 0.03 | Why? |
| Antigens, CD | 1 | 2018 | 984 | 0.03 | Why? |
| Biological Specimen Banks | 1 | 2021 | 1142 | 0.03 | Why? |
| Fibrosis | 1 | 2017 | 800 | 0.03 | Why? |
| Neuroimaging | 1 | 2020 | 1106 | 0.03 | Why? |
| Lumbar Vertebrae | 1 | 2014 | 196 | 0.03 | Why? |
| Follicle Stimulating Hormone, Human | 1 | 2011 | 12 | 0.03 | Why? |
| Alleles | 1 | 2018 | 1557 | 0.03 | Why? |
| Ultrasonography, Interventional | 1 | 2017 | 560 | 0.03 | Why? |
| Receptors, Tumor Necrosis Factor | 1 | 2011 | 40 | 0.03 | Why? |
| Myeloid Cells | 1 | 2017 | 808 | 0.03 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.03 | Why? |
| Immunomodulation | 1 | 2021 | 1472 | 0.03 | Why? |
| Anti-Mullerian Hormone | 1 | 2011 | 35 | 0.03 | Why? |
| Pneumonia, Viral | 1 | 2020 | 243684 | 0.03 | Why? |
| Image Processing, Computer-Assisted | 1 | 2020 | 1383 | 0.03 | Why? |
| Coronavirus Infections | 1 | 2020 | 253789 | 0.03 | Why? |
| Chemokines | 1 | 2017 | 1095 | 0.03 | Why? |
| Contrast Media | 1 | 2017 | 1011 | 0.03 | Why? |
| Single-Cell Analysis | 1 | 2021 | 2450 | 0.03 | Why? |
| Endothelial Cells | 1 | 2021 | 2048 | 0.03 | Why? |
| Mice, Transgenic | 1 | 2017 | 2739 | 0.03 | Why? |
| Phosphoproteins | 1 | 2021 | 4346 | 0.03 | Why? |
| Viral Load | 2 | 2021 | 15850 | 0.03 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.02 | Why? |
| Base Sequence | 1 | 2017 | 3581 | 0.02 | Why? |
| Immunity | 1 | 2020 | 2651 | 0.02 | Why? |
| Virus Diseases | 1 | 2006 | 3779 | 0.02 | Why? |
| Crohn Disease | 1 | 2017 | 959 | 0.02 | Why? |
| Transcriptome | 1 | 2020 | 3466 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2017 | 2742 | 0.02 | Why? |
| Structure-Activity Relationship | 1 | 2013 | 2219 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2021 | 4849 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2018 | 4758 | 0.02 | Why? |
| Amino Acid Sequence | 1 | 2017 | 6049 | 0.02 | Why? |
| Chronic Pain | 1 | 2014 | 736 | 0.02 | Why? |
| Adolescent | 4 | 2018 | 86841 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Administration, Oral | 1 | 2011 | 2340 | 0.02 | Why? |
| Risk | 1 | 2016 | 5288 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2019 | 9893 | 0.02 | Why? |
| Disability Evaluation | 1 | 2007 | 671 | 0.02 | Why? |
| Family | 1 | 2017 | 2909 | 0.02 | Why? |
| Brain | 1 | 2020 | 5133 | 0.02 | Why? |
| Risk Assessment | 2 | 2018 | 25439 | 0.02 | Why? |
| Protein Conformation | 1 | 2013 | 4386 | 0.01 | Why? |
| United States | 3 | 2018 | 46150 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 11367 | 0.01 | Why? |
| Coinfection | 1 | 2021 | 6820 | 0.01 | Why? |
| Prognosis | 1 | 2004 | 32490 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.01 | Why? |
| Betacoronavirus | 1 | 2020 | 204454 | 0.01 | Why? |
| Postoperative Complications | 1 | 2014 | 5861 | 0.01 | Why? |
| Incidence | 1 | 2016 | 25622 | 0.01 | Why? |
| International Cooperation | 1 | 2007 | 3436 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Pandemics | 1 | 2020 | 389249 | 0.01 | Why? |
| Europe | 1 | 2007 | 12702 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |